Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist, Takeda Announce Positive Phase 3 VERIFY Study Results
Details : PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist Therapeutics Updates on VERIFY Patient Enrollment and Timing of Top-line Data
Details : PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Protagonist Announces License and Collaboration Agreement with Takeda
Details : The collaboration supports PTG-300 (rusfertide) development for Polycythemia Vera, with the protagonist responsible for research and completing the Phase 3 trial and U.S. regulatory approval.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $300.0 million
March 18, 2024
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Takeda and Protagonist Enter Worldwide License for Rusfertide
Details : The collaboration supports the development of PTG-300 (rusfertide) for Polycythemia Vera. The protagonist is responsible for completing the Phase 3 trial and U.S. regulatory approval.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : $300.0 million
January 31, 2024
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Details : Rusfertide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Details : The net proceeds intends to fund the continued clinical development and pre-commercialization activities associated with PTG-300 (rusfertide), an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
April 04, 2023
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PTG-300 (rusfertide) is a hepcidin-mimetic that helps reduce iron availability to help achieve hematocrit control and decrease erythropoiesis in patients with polycythemia vera (PV) without the need for periodic therapeutic phlebotomy.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Details : Rusfertide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycythemia Vera.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The rasH2 signal also prompted a re-examination of the four cases of cancer observed across all rusfertide clinical trials involving over 160 patients, and a comprehensive review of the safety database, including cases of suspected unexpected serious adv...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 11, 2021
Lead Product(s) : Rusfertide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rusfertide
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Protagonist's rusfertide clinical trials have been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Protagonist is working closely with the FDA to determine next steps for the rusfertide development program.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Rusfertide
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable